Moreover, lentiviral vector-based gene therapy products directly injected into the target tissue include tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP-cyclohydrolase 1 (CH1) gene delivery in brain striatum for Parkinson’s disease [73]; endostatin and angiostatin gene transfer via subretinal injection to treat neovascular age-related macular degeneration (AMD) [74]; and ABCA4 gene delivery to the eyes of Stargardt Disease patients [75], all resulting in well-tolerated and sustained transgene expression. This evidence concerns the gene DDC and Parkinson disease.